Skip to main content
Premium Trial:

Request an Annual Quote

Orchid s Q3 Revenues Drop Slightly as Losses Shrink

NEW YORK, Nov. 11 (GenomeWeb News) - Orchid Biosciences reported a slight drop in revenues for the quarter ended Sept. 30, accompanied by shrinking R&D expenses and net losses.

The company's total quarterly revenues of $11.8 million were down from its third-quarter 2002 revenues of $13.3 million, which included $886,000 in revenues from the Life Sciences product business it sold in December 2002.

In a statement, Orchid said that "continued delays in the release of US federal National Institute of Justice funds to the states for forensic testing by private laboratories" had a negative impact on its third-quarter service revenues because "state and local governments have delayed issuing new contracts in anticipation of the expected new funding."

Despite the delay, Orchid is expecting total annual top-line revenues of approximately $50 million for 2003.

The company reported $552,000 in R&D expenses for the third quarter of 2003, down from $6.8 million in the year-ago period. Orchid attributed the drop in R&D spending to the divestiture of its SNP genotyping instrumentation business and the strategic realignment of the Orchid GeneShield business, "both of which were responsible for the majority of the research and development expenses in prior years," the company said in a statement.

Orchid's net losses also decreased year-over-year as a result of its restructuring, to $3.8 million for the third quarter of 2003 compared to $22.3 million in the third quarter of 2002.

As of Sept. 30, 2003, Orchid held cash and cash equivalents of $10.8 million.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.